Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Shares Issued (2016 - 2025)

IGC Pharma (IGC) has disclosed Shares Issued for 15 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 291.32% to $3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 442.31% increase, with the full-year FY2025 number at $4.5 million, up 790.8% from a year prior.
  • Shares Issued was $3.1 million for Q3 2025 at IGC Pharma, up from $852000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $14.2 million in Q1 2021 to a low of -$2.4 million in Q1 2024.
  • A 5-year average of $2.1 million and a median of $805000.0 in 2025 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 18487.01% in 2021, then plummeted 2191.26% in 2024.
  • IGC Pharma's Shares Issued stood at $3.4 million in 2021, then plummeted by 96.99% to $103000.0 in 2022, then surged by 2676.7% to $2.9 million in 2023, then tumbled by 87.9% to $346000.0 in 2024, then surged by 799.13% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Shares Issued are $3.1 million (Q3 2025), $852000.0 (Q2 2025), and $805000.0 (Q1 2025).